RODA VIVA | BRUNO HALPERN | 03/08/2026
Summary
Endocrinologist Bruno Hauptmann discusses obesity as a chronic disease and the rise of GLP-1 medications, criticizing the term "slimming pens" for trivializing treatment. He addresses the obesogenic environment, genetic factors, and the dangers of unregulated drug markets. The episode also covers public policy challenges, including SUS access, prevention strategies, and the social stigma surrounding obesity.
Topics discussed
Introduction of Roda Viva and guest Dr. Bruno Hauptmann
Obesity as a chronic disease and language stigma
Environmental, genetic, and social causes of obesity
Physiological mechanisms and the chronic nature of obesity
GLP-1 medications, costs, and SUS access in Brazil
Risks of counterfeit drugs and black market purchases
How GLP-1 and Tirzepatida medications work
Social inequality and luxury use of weight loss drugs
Manipulated pharmacies vs. industrial production risks
Public policy, prevention, and the cost of inaction
Medical training gaps and professional bias against obesity
Stigma, athlete use, and SUS incorporation protocols
Early life prevention and the 'first 1000 days'
Economic impact, future generics, and conclusion
Listen ad-free on Castria